Shareholder Vote

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549     FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): May 8, 2026   ABBVIE INC. (Exact name of registrant as specified in its charter)   Delaware   001-35565   32-0375147 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)         1 North Waukegan Road North Chicago , Illinois 60064-6400 (Address of principal executive offices)(Zip Code)    Registrant’s telephone number, including area code: ( 847 ) 932-7900   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange         NYSE Texas 0.750% Senior Notes due 2027   ABBV27   New York Stock Exchange 2.125% Senior Notes due 2028   ABBV28   New York Stock Exchange 2.625% Senior Notes due 2028   ABBV28B   New York Stock Exchange 2.125% Senior Notes due 2029   ABBV29   New York Stock Exchange 1.250% Senior Notes due 2031   ABBV31   New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           Item 5.07 Submission of Matters to a Vote of Security Holders.   AbbVie held its 2026 Annual Meeting of Stockholders on May 8, 2026. The following is a summary of the matters voted on at that meeting.   (1) The stockholders elected AbbVie’s Class II directors with terms expiring in 2029, as follows:   Name   For     Against     Abstain     Broker Non-Votes Jennifer L. Davis   1,216,558,754     89,839,329     2,680,369     239,399,581 Melody B. Meyer   1,284,771,578     22,470,074     1,836,800     239,399,581 Robert A. Michael   1,221,224,370     85,865,852     1,988,230     239,399,581 Frederick H. Waddell   1,225,237,825     81,747,033     2,093,594     239,399,581   (2) The stockholders ratified the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2026, as follows:   For     Against     Abstain 1,522,575,012     23,766,564     2,136,457   (3) The stockholders approved, on an advisory basis, the compensation of AbbVie’s named executive officers, as follows:   For     Against     Abstain     Broker Non-Votes 1,228,615,745     69,336,359     11,126,348     239,399,581   (4) The stockholders did not approve the management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting, as follows:   For     Against     Abstain     Broker Non-Votes 1,290,990,023     14,896,119     3,192,310     239,399,581   (5) The stockholders did not approve a stockholder proposal to adopt a policy to require an independent chair, as follows:   For     Against     Abstain     Broker Non-Votes 515,626,009     787,253,970     6,198,473     239,399,581         SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.         ABBVIE INC.         Date: May 12, 2026 By: /s/ Perry C. Siatis       Perry C. Siatis       Executive Vice President, General Counsel and Secretary